News
BCLI
0.5320
+3.44%
0.0177
Brainstorm Cell Therapeutics Executive Leadership Changes
TipRanks · 2d ago
BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer
Seeking Alpha · 2d ago
Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
Benzinga · 2d ago
Brainstorm Cell Therapeutics (BCLI) Price Target Increased by 150.00% to 2.55
NASDAQ · 2d ago
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
BrainStorm Cell Therapeutics named a new medical chief ahead of a long-awaited clinical trial. Co-Chief Executive Stacy Lindborg will step down but remain on the company's board. The New York-based company is developing stem-cell therapeutics. BrainStorm also named Bob Dagher as chief medical officer. Dagher will oversee a clinical trial of its therapy to treat ALS.
Dow Jones · 3d ago
*BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
Dow Jones · 3d ago
*BrainStorm Cell Therapeutics: Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors >GHDN.BE
Dow Jones · 3d ago
BRAINSTORM CELL THERAPEUTICS INC - STACY LINDBORG STEPPING DOWN AS CO-CEO AND TRANSITIONING TO BOARD OF DIRECTORS
Reuters · 3d ago
Press Release: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn. Dr. Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg stepping down as Co-CEO and Transitioning to Board of Directors. The Company is a leading developer of adult stem cell therapeutics for neurodegenerative diseases. NurOwn is a cell therapy treatment for amyotrophic lateral sclerosis.
Dow Jones · 3d ago
Weekly Report: what happened at BCLI last week (0408-0412)?
Weekly Report · 4d ago
*BrainStorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Market Value Rule
Dow Jones · 04/11 10:00
BRAINSTORM CELL THERAPEUTICS INC: NUROWN TREATMENT RESULTED IN A POSITIVE IMPACT ON IMPORTANT CSF BIOMARKERS RELEVANT TO ALS COMPARED TO PLACEBO
Reuters · 04/10 10:00
BUZZ-U.S. STOCKS ON THE MOVE-Chemours, Lucid, OppFi
U.S. Stocks reverse early gains ahead of key inflation print. Dow Jones Industrial Average down 0.36%; S&P 500 and Nasdaq Composite also down. Chemours, Lucid, OppFi among the top stocks on the move. Lucid Group down 3.9% after announcing potential sale of parts of company.
Reuters · 04/09 18:19
BUZZ-U.S. STOCKS ON THE MOVE-Digital Realty, Alphabet, Moderna
Dow Jones Industrial Average was down 0.52% on Tuesday. Wall Street's main stock indexes gained on Tuesday supported by retreating Treasury yields. Investors await a key inflation print later in the week that could help shape the Fed's stance on interest-rate cuts. Digital Realty, Alphabet, Moderna are among the day's top stocks.
Reuters · 04/09 16:20
BUZZ-U.S. STOCKS ON THE MOVE-Bloom Energy, Hecla Mining, Alkermes
U.S. Stocks were poised for a higher open on Tuesday. Dow e-minis were up 0.05% ahead of a key inflation print later in the week. Top three NYSE percentage gainers premarket were Leju Holdings, Hecla Mining. Bloom Energy, American Eagle Outfitters, Alkermes among stocks on the move.
Reuters · 04/09 13:23
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Acrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.3% to $10.19 during Tuesday's pre-market session. MyMD Pharmaceuticals stock rose 33.85% and Addex Therapeutic stock rose 24.48% during the same session. Other gainers included Vincerx Pharma, Neogen and Tilray Brands.
Benzinga · 04/09 12:09
BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Taysha Gene, American Eagle
U.S. Stock index futures were flat on Tuesday ahead of a crucial inflation reading later in the week. Gold miners, Taysha Gene, American Eagle and Bloom Energy are among the top stocks on the move. Dow e-minis were down 0.02% ahead of the open.
Reuters · 04/09 11:54
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday morning. Biophytis stock is rocketing close to 50% after announcing its 2023 results. Moving stocks this morning are earnings reports, clinical trial data and more. Biggest Pre-Market Stock Movers include 10 top gainers and 10 top losers.
Investorplace · 04/09 11:27
BUZZ-BrainStorm rises on deal with US FDA on study design for ALS therapy
BrainStorm Cell Therapeutics rises on deal with US FDA on study design for ALS therapy. Shares of BrainStorm rise 6.6% to 77 cents premarket. Co says it has entered into agreement with FDA on design for a late-stage study testing its ALS therapy NurOwn.
Reuters · 04/09 11:14
BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy
BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy for cell therapy candidate NurOwn for amyotrophic lateral sclerosis. The two-part trial is expected to start in 2024 for patients with the neurological disease. Brainstorm Cell Therapeutics traded higher in the premarket Tuesday.
Seeking Alpha · 04/09 10:58
More
Webull provides a variety of real-time BCLI stock news. You can receive the latest news about Brainstorm Cell Therapeutics I through multiple platforms. This information may help you make smarter investment decisions.
About BCLI
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.